CDR-restricted engineering of native human scFvs creates highly stable and soluble bifunctional antibodies for subcutaneous delivery

mAbs

Volumn 5, Issue 6, 2013, Pages 882-895

  Fennell, Brian J ^a   McDonnell, Barry ^a   Tam, Amy Sze Pui ^a   Chang, Lijun ^b   Steven, John ^b   Broadbent, Ian D ^b   Gao, Huilan ^a   Kieras, Elizabeth ^a   Alley, Jennifer ^a   Luxenberg, Deborah ^a   Edmonds, Jason ^a   Fitz, Lori J ^a   Miao, Wenyan ^a   Whitters, Matthew J ^a   Medley, Quintus G ^a   Guo, Yongjing J ^a   Darmanin Sheehan, Alfredo ^a   Autin, Bénédicte ^a   Shúilleabháin, Deirdre Ní ^a   Cummins, Emma ^a   King, Amy ^a   Krebs, Mark R H ^a   Grace, Christopher ^b   Hickling, Timothy P ^b   Boisvert, Angela ^a   Zhong, Xiaotian ^a   McKenna, Matthew ^a   Francis, Christopher ^a   Olland, Stephane ^a   Bloom, Laird ^a   Paulsen, Janet ^a   Somers, Will ^a   Jensen, Allan ^a   Lin, Laura ^a   Finlay, William J J ^a   Cunningham, Orla ^a   more..

^a PFIZER INC   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Affinity optimization; Bispecific scFv Fc scFv; High concentration formulation; Phage display; Thermal stability

Indexed keywords

BISPECIFIC ANTIBODY; CXCL13 CHEMOKINE; LEAD; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; COMPLEMENTARITY DETERMINING REGION; PEPTIDE LIBRARY;

ANIMAL EXPERIMENT; ANTIBODY ENGINEERING; ARTICLE; CELL SURFACE; COMPLEMENTARITY DETERMINING REGION; CONTROLLED STUDY; CROSS REACTION; FEMALE; GENE MUTATION; HUMAN; IMMUNOMODULATION; INFLAMMATORY CELL; MOLECULAR WEIGHT; MUTAGENESIS; NONHUMAN; PHAGE DISPLAY; RAT; THERMOSTABILITY; ANIMAL; BACTERIOPHAGE; CHEMISTRY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; METABOLISM; PEPTIDE LIBRARY; PROTEIN ENGINEERING; PROTEIN STABILITY; SUBCUTANEOUS DRUG ADMINISTRATION; TEMPERATURE;

ANIMALS; ANTIBODIES, BISPECIFIC; BACTERIOPHAGES; COMPLEMENTARITY DETERMINING REGIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; PEPTIDE LIBRARY; PROTEIN ENGINEERING; PROTEIN STABILITY; RATS; SINGLE-CHAIN ANTIBODIES; TEMPERATURE;

EID: 84889822148     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.26201     Document Type: Article

References (30)

1. Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 2010; 10:301-16; PMID:20414204; http://dx.doi.org/10.1038/nri2761
2. Miller BR, Demarest SJ, Lugovskoy A, Huang F, Wu X, Snyder WB, Croner LJ, Wang N, Amatucci A, Michaelson JS, et al. Stability engineering of scFvs for the development of bispecific and multivalent antibodies. Protein Eng Des Sel 2010; 23:549-57; PMID:20457695; http://dx.doi.org/10.1093/protein/gzq028
3. Xu L, Kohli N, Rennard R, Jiao Y, Razlog M, Zhang K, Baum J, Johnson B, Tang J, Schoeberl B, et al. Rapid optimization and prototyping for therapeutic antibody-like molecules. MAbs 2013; 5:237-54; PMID:23392215; http://dx.doi.org/10.4161/mabs.23363
4. Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, Noppeney R, Viardot A, Hess G, Schuler M, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008; 321:974-7; PMID:18703743; http://dx.doi.org/10.1126/science.1158545
5. Topp MS, Gökbuget N, Zugmaier G, Degenhard E, Goebeler ME, Klinger M, Neumann SA, Horst HA, Raff T, Viardot A, et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood 2012; 120:5185-7; PMID:23024237; http://dx.doi.org/10.1182/blood-2012-07-441030
6. Sebastian M, Kiewe P, Schuette W, Brust D, Peschel C, Schneller F, Rühle KH, Nilius G, Ewert R, Lodziewski S, et al. Treatment of malignant pleural effusion with the trifunctional antibody catumaxomab (Removab) (anti-EpCAM x Anti-CD3): results of a phase 1/2 study. J Immunother 2009; 32:195-202; PMID:19238019; http://dx.doi.org/10.1097/CJI.0b013e318195b5bb
7. Sebastian M, Kuemmel A, Schmidt M, Schmittel A. Catumaxomab: a bispecific trifunctional antibody. Drugs Today (Barc) 2009; 45:589-97; PMID:19927225; http://dx.doi.org/10.1358/dot.2009.45.8.1401103
8. Sebastian M, Passlick B, Friccius-Quecke H, Jäger M, Lindhofer H, Kanniess F, Wiewrodt R, Thiel E, Buhl R, Schmittel A. Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): a phase I study. Cancer Immunol Immunother 2007; 56:1637-44; PMID:17410361; http://dx.doi.org/10.1007/s00262-007-0310-7
9. Röthlisberger D, Honegger A, Plückthun A. Domain interactions in the Fab fragment: a comparative evaluation of the single-chain Fv and Fab format engineered with variable domains of different stability. J Mol Biol 2005; 347:773-89; PMID:15769469; http://dx.doi.org/10.1016/j.jmb.2005.01.053
10. Mabry R, Gilbertson DG, Frank A, Vu T, Ardourel D, Ostrander C, Stevens B, Julien S, Franke S, Meengs B, et al. A dual-targeting PDGFRbeta/VEGF-A molecule assembled from stable antibody fragments demonstrates anti-angiogenic activity in vitro and in vivo. MAbs 2010; 2:20-34; PMID:20065654; http://dx.doi.org/10.4161/mabs.2.1.10498
11. Mabry R, Lewis KE, Moore M, McKernan PA, Bukowski TR, Bontadelli K, Brender T, Okada S, Lum K, West J, et al. Engineering of stable bispecific antibodies targeting IL-17A and IL-23. Protein Eng Des Sel 2010; 23:115-27; PMID:20022918; http://dx.doi.org/10.1093/protein/gzp073
12. Orcutt KD, Ackerman ME, Cieslewicz M, Quiroz E, Slusarczyk AL, Frangioni JV, Wittrup KD. A modular IgG-scFv bispecific antibody topology. Protein Eng Des Sel 2010; 23:221-8; PMID:20019028; http://dx.doi.org/10.1093/protein/gzp077
13. Michaelson JS, Demarest SJ, Miller B, Amatucci A, Snyder WB, Wu X, Huang F, Phan S, Gao S, Doern A, et al. Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR. MAbs 2009; 1:128-41; PMID:20061822; http://dx.doi.org/10.4161/mabs.1.2.7631
14. Jordan JL, Arndt JW, Hanf K, Li G, Hall J, Demarest S, Huang F, Wu X, Miller B, Glaser S, et al. Structural understanding of stabilization patterns in engineered bispecific Ig-like antibody molecules. Proteins 2009; 77:832-41; PMID:19626705; http://dx.doi.org/10.1002/prot.22502
15. Andris-Widhopf J, Rader C, Steinberger P, Fuller R, Barbas CF 3rd. Methods for the generation of chicken monoclonal antibody fragments by phage display. J Immunol Methods 2000; 242:159-81; PMID:10986398; http://dx.doi.org/ 10.1016/S0022-1759(00)00221-0
16. Nissim A, Hoogenboom HR, Tomlinson IM, Flynn G, Midgley C, Lane D, Winter G. Antibody fragments from a 'single pot' phage display library as immunochemical reagents. EMBO J 1994; 13:692-8; PMID:7508862
17. Mahon CM, Lambert MA, Glanville J, Wade JM, Fennell BJ, Krebs MR, Armellino D, Yang S, Liu X, O'Sullivan CM, et al. Comprehensive interrogation of a minimalist synthetic CDR-H3 library and its ability to generate antibodies with therapeutic potential. J Mol Biol 2013; 425:1712-30; PMID:23429058; http://dx.doi.org/10.1016/j.jmb.2013.02.015
18. Bazin-Redureau MI, Renard CB, Scherrmann JM. Pharmacokinetics of heterologous and homologous immunoglobulin G, F(ab')2 and Fab after intravenous administration in the rat. J Pharm Pharmacol 1997; 49:277-81; PMID:9231345; http://dx.doi.org/10.1111/j.2042-7158.1997.tb06795.x
19. Barbas CF 3rd, Bain JD, Hoekstra DM, Lerner RA. Semisynthetic combinatorial antibody libraries: a chemical solution to the diversity problem. Proc Natl Acad Sci U S A 1992; 89:4457-61; PMID:1584777; http://dx.doi.org/10. 1073/pnas.89.10.4457
20. Bostrom J, Lee CV, Haber L, Fuh G. Improving antibody binding affinity and specificity for therapeutic development. [xiii.]. Methods Mol Biol 2009; 525:353-76, xiii; PMID:19252851; http://dx.doi.org/10.1007/978-1-59745-554-1-19
21. King AC, Woods M, Liu W, Lu Z, Gill D, Krebs MR. High-throughput measurement, correlation analysis, and machine-learning predictions for pH and thermal stabilities of Pfizer-generated antibodies. Protein Sci 2011; 20:1546-57; PMID:21710487; http://dx.doi.org/10.1002/pro.680
22. Chaudhary VK, Gallo MG, FitzGerald DJ, Pastan I. A recombinant single-chain immunotoxin composed of anti-Tac variable regions and a truncated diphtheria toxin. Proc Natl Acad Sci U S A 1990; 87:9491-4; PMID:2251289; http://dx.doi.org/10.1073/pnas.87.23.9491
23. Zahnd C, Sarkar CA, Plückthun A. Computational analysis of off-rate selection experiments to optimize affinity maturation by directed evolution. Protein Eng Des Sel 2010; 23:175-84; PMID:20130104; http://dx.doi.org/10.1093/ protein/gzp087
24. He F, Becker GW, Litowski JR, Narhi LO, Brems DN, Razinkov VI. High-throughput dynamic light scattering method for measuring viscosity of concentrated protein solutions. Anal Biochem 2010; 399:141-3; PMID:19995543; http://dx.doi.org/10.1016/j.ab.2009.12.003
25. Finlay WJ, Cunningham O, Lambert MA, Darmanin-Sheehan A, Liu X, Fennell BJ, Mahon CM, Cummins E, Wade JM, O'Sullivan CM, et al. Affinity maturation of a humanized rat antibody for anti-RAGE therapy: comprehensive mutagenesis reveals a high level of mutational plasticity both inside and outside the complementarity-determining regions. J Mol Biol 2009; 388:541-58; PMID:19285987; http://dx.doi.org/10.1016/j.jmb.2009.03.019
26. Finlay WJ, Bloom L, Cunningham O. Optimized generation of high-affinity, high-specificity single-chain Fv antibodies from multiantigen immunized chickens. Methods Mol Biol 2011; 681:383-401; PMID:20978977; http://dx.doi.org/10.1007/978-1-60761-913-0-21
27. Jespers L, Schon O, Famm K, Winter G. Aggregation-resistant domain antibodies selected on phage by heat denaturation. Nat Biotechnol 2004; 22:1161-5; PMID:15300256; http://dx.doi.org/10.1038/nbt1000
28. Cummins E, Luxenberg DP, McAleese F, Widom A, Fennell BJ, Darmanin-Sheehan A, Whitters MJ, Bloom L, Gill D, Cunningham O. A simple high-throughput purification method for hit identification in protein screening. J Immunol Methods 2008; 339:38-46; PMID:18760282; http://dx.doi.org/10.1016/j. jim.2008.07.016
29. Myszka DG. Improving biosensor analysis. J Mol Recognit 1999; 12:279-84; PMID:10556875; http://dx.doi.org/10.1002/(SICI)1099-1352(199909/10)12:5<279:: AID-JMR473>3.0.CO;2-3
30. Kortt AA, Gruen LC, Oddie GW. Influence of mass transfer and surface ligand heterogeneity on quantitative BIAcore binding data. Analysis of the interaction of NC10 Fab with an anti-idiotype Fab'. J Mol Recognit 1997; 10:148-58; PMID:9408831; http://dx.doi.org/10.1002/(SICI)1099-1352(199705/06)10: 3<148::AID-JMR360>3.0.CO;2-F